What Celator's Success In AML Means For Actinium Pharma

March 31, 2016 - PRLog -- Earlier in March 2016, Celator Pharmaceuticals (CPXX) announced positive top-line results from the company's Phase 3 clinical trial testing VYXEOS™ (cytarabine + daunorubicin liposome injection) in patients with high-risk (secondary) acute myeloid leukemia (AML) compared to the standard of care regimen of cytarabine and daunorubicin known as "7+3". The trial met its primary endpoint demonstrating a statistically significant improvement in overall survival (OS). Specifically, patients on VYXEOS had a median OS of 9.56 months compared to 5.95 months for the current 7+3 standard of care. The results were statistically significant (p=0.005) with a hazard ratio of 0.69, representing a 31% reduction in risk of death in favor of VYXEOS. Full data from the Celator Phase 3 trial will be presented at the American Society of Clinical Oncology 2016 Annual Meeting in June 2016.

Celator shares are up over 600%, from $1.50 to $11.00 per share on this very positive news. It is the perfect example of why investors put money into small-cap biotech stocks. The risks are high, but so are the rewards, and Celator shareholders hit one out of the park last week. I have not written before on Celator; however, I have written extensively on Actinium Pharmaceuticals (ATNM), another small-cap biotech company trading around $2.00 per share with two drug candidates under development for AML.

Since the Celator news, I've received several questions from investors on what exactly the VYXEOS data means for Actinium. Below I attempt to put the positive VYXEOS news in context as it relates to Actinium's Iomab-B and Actimab-A, and hopefully clear up some confusion with respect to the differing strategies of the two companies.

Please read the full article here >> http://www.bionapcfa.com/2016/03/what-celators-success-in...